9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Clinical trial NCT05239182 · TERMINATED

Trial details

NCT number: NCT05239182
Sponsor: Anwaar Saeed
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Adenocarcinoma

Start date: 2022-01-26
Primary completion: 2022-12-20
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.